Warning letter
Shilpa Medicare Limited: warning letter of Oct 9, 2020
FDA warning letter 607877 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 607877 |
|---|---|
| Company | Shilpa Medicare Limited |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Oct 9, 2020 |
| Posted date | Oct 27, 2020 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| CFR sections cited | 211.34, 211.192, 211.198(a), 314.81(b)(1), 314.81(b)(1)(i), 314.81(b)(1)(ii) |
| Inspection city | Jadcherla, Mahabubnagar District |
| Inspection start date | Feb 13, 2020 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: